Leading specialists in iron deficiency convene at the largest global multi-disciplinary educational event dedicated to the topic (3rd European Iron Academy)
The 3rd European Iron Academy (EIA) will take place on the 12th and 13th September 2016 in Berlin, Germany, and will bring together over 450 clinicians with an interest in iron deficiency. Iron deficiency is the most common nutritional disorder in the world and is the leading cause of anaemia2. The condition occurs frequently across multiple therapeutic areas e.g. in patients with chronic diseases such as inflammatory bowel disease, heart failure and chronic kidney disease3. In such conditions, inadequately managed iron deficiency has been associated with poor patient outcomes, including increased hospitalisations, reduced quality of life and even higher mortality rates4-7.
The 3rd EIA has the goal of further raising awareness of iron deficiency and stimulating discussion amongst peers, helping them to better understand the causes, the need for improved diagnosis and the current treatment options for their patients. The 2016 programme offers delegates the opportunity to tailor the sessions to their own clinical interests/areas of expertise; engage in interactive patient case scenarios and breakout sessions; and discuss current standards in iron deficiency management with experts in Q&A-style sessions. The 3rd EIA is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide participants with CME credits, and is supported by an educational grant from Vifor Pharma.
“We are delighted to be running the 3rd European Iron Academy this year, which specifically addresses the need for continuing medical education on iron deficiency,” said Professor Stefan Anker (Germany), EIA 2016 co-Chair and Professor of Innovative Clinical Trials at the University Medical Center Göttingen, Germany. “This year’s programme will review the latest data relating to the diagnosis and treatment of iron deficiency within a number of key therapy areas, including cardiology, gastroenterology, nephrology and haematology.”
The EIA will use an all-encompassing approach to education and to improving patient outcomes in many disease areas.
About the European Iron Academy
The European Iron Academy is an independent educational event developed and organised by a Steering Committee of international experts in iron deficiency and iron deficiency anaemia, which will bring together medical specialists with the aim of achieving the following objectives related to the topic:
- Convey the latest knowledge in iron deficiency and iron deficiency anaemia
- Discuss safety and best practice in the treatment
- Discuss the global burden, prevalence and real-world impact across different specialties
- Share practical clinical experiences across different specialities and treatment settings
This year’s EIA will build on the successes of previous Iron Academy meetings, which were annually held at the national-level in Switzerland since 2008, and the 2nd EIA, held in Paris in March 2015. For more information about this year’s EIA and the previous two meetings, please visit: http://europeanironacademy.org/
About Vifor Pharma
Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. For more information about Vifor Pharma, please visit www.viforpharma.com.
1. Unicef http://www.unicef.org/nutrition/23964_iron.html Last accessed: 10 November 2014
2. Kassebaum J. The Global Burden of Anemia. Hematol Oncol Clin N Am. 30, 247–308, doi:10.1016/j.hoc.2015.11.002 (2016).
3. Donovan, A., Roy, C. N. & Andrews, N. C. The ins and outs of iron homeostasis. Physiology 21, 115-123, doi:10.1152/physiol.00052.2005 (2006).
4. Lopez, A et al. Iron deficiency anaemia. The Lancet. 27, 387(10021), doi: 10.1016/S0140-6736(15)60865-0 (2016).
5. Koduru, P & Abraham, BP The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal diseases. Therapeutic advances in Gastroenterology. 9, 76–85, doi:10.1177/1756283X15616577 (2016).
6. Jankowska, EA et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. European Journal of Heart Failure. 18, 786-95, doi:10.1002/ejhf.473 (2016).
7. Nuñez, J et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. European Journal of Heart Failure. 18, 798-802, doi:10.1002/ejhf.513 (2016).
Madano for European Iron Academy
Dr Reghu Venkatesan
Telephone: +44 (0)20 3595 2590
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom